Coherus Oncology, Inc.
CHRS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $267 | $257 | $211 | $327 |
| % Growth | 3.8% | 21.9% | -35.4% | – |
| Cost of Goods Sold | $118 | $159 | $70 | $58 |
| Gross Profit | $149 | $98 | $141 | $269 |
| % Margin | 56% | 38.2% | 66.8% | 82.4% |
| R&D Expenses | $93 | $109 | $199 | $363 |
| G&A Expenses | $140 | $175 | $188 | $161 |
| SG&A Expenses | $150 | $186 | $198 | $170 |
| Sales & Mktg Exp. | $11 | $11 | $11 | $9 |
| Other Operating Expenses | $17 | $6 | $0 | $0 |
| Operating Expenses | $261 | $301 | $398 | $533 |
| Operating Income | -$112 | -$203 | -$257 | -$264 |
| % Margin | -41.8% | -79% | -121.7% | -80.8% |
| Other Income/Exp. Net | $140 | -$35 | -$35 | -$23 |
| Pre-Tax Income | $29 | -$238 | -$292 | -$287 |
| Tax Expense | $0 | -$0 | $0 | $0 |
| Net Income | $29 | -$238 | -$292 | -$287 |
| % Margin | 10.7% | -92.5% | -138.2% | -87.9% |
| EPS | 0.25 | -2.53 | -3.76 | -3.81 |
| % Growth | 109.9% | 32.7% | 1.3% | – |
| EPS Diluted | 0.25 | -2.53 | -3.76 | -3.81 |
| Weighted Avg Shares Out | 115 | 94 | 78 | 75 |
| Weighted Avg Shares Out Dil | 115 | 94 | 78 | 75 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $27 | $41 | $32 | $23 |
| Depreciation & Amortization | $5 | $4 | $4 | $3 |
| EBITDA | $61 | -$194 | -$256 | -$261 |
| % Margin | 22.8% | -75.4% | -121.1% | -79.8% |